false FY 0001672571 0001672571 2025-04-01 2026-03-31 0001672571 2025-09-30 0001672571 2026-03-31 0001672571 2025-03-31 0001672571 us-gaap:RelatedPartyMember 2026-03-31 0001672571 us-gaap:RelatedPartyMember 2025-03-31 0001672571 us-gaap:CommonClassAMember 2026-03-31 0001672571 us-gaap:CommonClassAMember 2025-03-31 0001672571 us-gaap:CommonClassBMember 2026-03-31 0001672571 us-gaap:CommonClassBMember 2025-03-31 0001672571 us-gaap:CommonClassCMember 2026-03-31 0001672571 us-gaap:CommonClassCMember 2025-03-31 0001672571 AAQL:CommonClassDMember 2026-03-31 0001672571 AAQL:CommonClassDMember 2025-03-31 0001672571 AAQL:CommonClassEMember 2026-03-31 0001672571 AAQL:CommonClassEMember 2025-03-31 0001672571 2024-04-01 2025-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001672571 us-gaap:RetainedEarningsMember 2025-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001672571 us-gaap:RetainedEarningsMember 2024-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001672571 2024-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-04-01 2026-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2026-03-31 0001672571 us-gaap:RetainedEarningsMember 2025-04-01 2026-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2026-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-04-01 2025-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2025-03-31 0001672571 us-gaap:RetainedEarningsMember 2024-04-01 2025-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2025-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2026-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001672571 us-gaap:RetainedEarningsMember 2026-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001672571 AAQL:StockPurchaseAgreementMember AAQL:Dazhong368IncMember 2019-06-30 2019-07-01 0001672571 AAQL:Dazhong368IncMember AAQL:StockPurchaseAgreementMember 2019-07-01 0001672571 AAQL:MRBarryWanMember AAQL:StockPurchaseAgreementMember 2023-04-09 2023-04-10 0001672571 AAQL:MRBarryWanMember AAQL:StockPurchaseAgreementMember 2023-04-10 0001672571 AAQL:PeriodEndRMBMember 2026-03-31 0001672571 AAQL:AverageRMBMember 2026-03-31 0001672571 AAQL:PeriodEndRMBMember 2025-03-31 0001672571 AAQL:AverageRMBMember 2025-03-31 0001672571 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001672571 us-gaap:OfficeEquipmentMember 2026-03-31 0001672571 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001672571 us-gaap:OfficeEquipmentMember 2025-03-31 0001672571 us-gaap:PatentsMember 2026-03-31 0001672571 us-gaap:PatentsMember 2025-03-31 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingLoanMember 2024-12-31 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingOfMaturityLoanMember 2024-12-31 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingOfMaturityLoanMember 2024-12-31 2024-12-31 0001672571 us-gaap:NonrelatedPartyMember 2025-03-24 0001672571 us-gaap:NonrelatedPartyMember 2025-03-24 2025-03-24 0001672571 AAQL:TripartiteDebtAssignmentAgreementMember 2025-03-31 0001672571 AAQL:TripartiteDebtAssignmentAgreementMember 2025-11-25 0001672571 AAQL:TwoPromissoryNotesMember 2025-11-25 2025-11-25 0001672571 AAQL:MRBarryWanMember AAQL:OneConsolidatedNoteMember 2025-11-25 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingLoanMember AAQL:OneConsolidatedNoteMember 2025-11-25 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingOfMaturityLoanMember AAQL:OneConsolidatedNoteMember 2025-11-25 0001672571 AAQL:MRBarryWanMember AAQL:SecondConsolidatedNoteMember 2025-11-25 0001672571 AAQL:NewLivingMember AAQL:SecondConsolidatedNoteMember 2025-11-25 0001672571 AAQL:TwoPromissoryNotesMember us-gaap:CommonClassAMember 2025-11-25 0001672571 AAQL:NovemberDebtAssignmentAgreementsMember 2025-11-25 0001672571 AAQL:NovemberDebtAssignmentAgreementsMember 2025-11-25 2025-11-25 0001672571 us-gaap:NonrelatedPartyMember 2026-03-31 0001672571 AAQL:MrWanMember 2026-03-31 0001672571 AAQL:MrWanMember 2025-03-31 0001672571 srt:ScenarioForecastMember 2027-12-09 2027-12-09 0001672571 srt:ScenarioForecastMember 2029-12-31 2029-12-31 0001672571 us-gaap:RelatedPartyMember 2026-03-31 0001672571 us-gaap:RelatedPartyMember 2025-03-31 0001672571 AAQL:MrWanMember 2024-12-31 0001672571 AAQL:MrWanMember 2024-12-31 2024-12-31 0001672571 AAQL:MRBarryWanMember 2025-03-31 0001672571 2025-11-25 0001672571 AAQL:MrWanSpouseMember 2024-12-31 0001672571 AAQL:MrWanSpouseMember 2024-12-31 2024-12-31 0001672571 us-gaap:RelatedPartyMember AAQL:MrWanSpouseMember 2025-03-24 0001672571 AAQL:NewLivingMember 2024-12-31 0001672571 AAQL:NewLivingMember 2024-12-31 2024-12-31 0001672571 2008-01-01 2008-01-01 0001672571 country:CN 2025-04-01 2026-03-31 0001672571 country:US 2025-04-01 2026-03-31 0001672571 country:US 2024-04-01 2025-03-31 0001672571 country:HK 2025-04-01 2026-03-31 0001672571 country:HK 2024-04-01 2025-03-31 0001672571 country:CN 2024-04-01 2025-03-31 0001672571 2024-06-05 0001672571 2024-06-06 0001672571 us-gaap:CommonClassAMember 2024-06-06 0001672571 us-gaap:CommonClassBMember 2024-06-06 0001672571 us-gaap:CommonClassCMember 2024-06-06 0001672571 AAQL:CommonClassDMember 2024-06-06 0001672571 AAQL:CommonClassEMember 2024-06-06 0001672571 AAQL:SalesOfGoodsMember 2025-04-01 2026-03-31 0001672571 AAQL:SalesOfGoodsMember 2024-04-01 2025-03-31 0001672571 us-gaap:TechnologyServiceMember 2025-04-01 2026-03-31 0001672571 us-gaap:TechnologyServiceMember 2024-04-01 2025-03-31 0001672571 AAQL:OfflinePhysicalTherapyServicesMember 2025-04-01 2026-03-31 0001672571 AAQL:OfflinePhysicalTherapyServicesMember 2024-04-01 2025-03-31 0001672571 country:US 2026-03-31 0001672571 country:US 2025-03-31 0001672571 country:CN 2026-03-31 0001672571 country:CN 2025-03-31 0001672571 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AAQL:SingleCustomerMember 2024-04-01 2025-03-31 0001672571 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AAQL:CustomerOneMember 2025-04-01 2026-03-31 0001672571 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AAQL:CustomerTwoMember 2025-04-01 2026-03-31 0001672571 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember AAQL:SupplierOneMember 2025-04-01 2026-03-31 0001672571 AAQL:OperatingLeaseAgreementMember us-gaap:SubsequentEventMember 2026-04-01 0001672571 AAQL:OperatingLeaseAgreementMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CNY AAQL:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended: March 31, 2026

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number: 000-56157

Antiaging Quantum Living Inc.

(Exact name of small business issuer as specified in its charter)

New York

47-2643986

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification No.)

135-27 38th Ave #388

Flushing, NY 11354

(Address of principal executive offices) (Zip Code)

+1 929-990-3255

(Registrant’s telephone number, including area code)

Former address: 133-27 39th Ave Ths #PH2A

Flushing, NY 11354

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Not Applicable		Not Applicable		Not Applicable

Securities registered pursuant to Section 12(g) of the Act: Class A Common Stock

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark whether the issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a small. See definition of “large accelerated filer, accelerated filer and smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

	Large accelerated filer ☐	Accelerated filer ☐
	Non-accelerated filer ☐	Smaller reporting company ☒
		Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. The aggregate market value of the voting and non-voting shares of the Company’s Class A common stock held by non-affiliates based on the last sale of the Class A Common Stock on September 30, 2025, was $779,500.

Number of shares outstanding of each of the issuer’s classes of common stock on March 31, 2026: Class A Common Stock: 34,275,340.

TABLE OF CONTENTS

Note About Forward-Looking Statements		3

PART I		3

Item 1.	Business	3

Item 1A.	Risk Factors	5

Item 1B.	Unresolved Staff Comments	5

Item 1C.	Cybersecurity	5

Item 2.	Properties	5

Item 3.	Legal Proceedings	5

Item 4.	Mine Safety Disclosures	5

PART II		6

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	6

Item 6.	Selected Financial Data	8

Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	8

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	12

Item 8.	Financial Statements and Supplementary Data	12

Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	13

Item 9A.	Controls and Procedures	13

Item 9B.	Other Information	14

PART III		15

Item 10.	Directors, Executive Officers and Corporate Governance	15

Item 11.	Executive Compensation	16

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	17

Item 13.	Certain Relationships and Related Transactions, and Director Independence	18

Item 14.	Principal Accounting Fees and Services	18

PART IV		19

Item 15.	Exhibits, Financial Statement Schedules	19

Signatures		20

NOTE ABOUT FORWARD-LOOKING STATEMENTS

The information contained in this Report includes some statements that are not purely historical and that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward-looking statements relate to, among other things, expectations of the business environment in which we operate, perceived opportunities in the market and statements regarding our mission and vision. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You can generally identify forward-looking statements as statements containing the words “anticipates,” “believes,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “possible,” “potential,” “predicts,” “projects,” “seeks,” “should,” “will,” “would” and similar expressions, or the negatives of such terms, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements involve risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The forward-looking statements contained herein are based on various assumptions, many of which are based, in turn, upon further assumptions. Our expectations, beliefs and forward-looking statements are expressed in good faith on the basis of management’s views and assumptions as of the time the statements are made, but there can be no assurance that management’s expectations, beliefs or projections will result or be achieved or accomplished.

In addition to other factors and matters discussed elsewhere herein, the following are important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements: technological advances, impact of competition, dependence on key personnel and the need to attract new management, effectiveness of cost and marketing efforts, acceptances of products, ability to expand markets and the availability of capital or other funding on terms satisfactory to us. We disclaim any obligation to update forward-looking statements to reflect events or circumstances after the date hereof.

Unless expressly indicated or the context requires otherwise, the terms “Antiaging,” “Company,” “we,” “us,” and “our” in this document refer to Antiaging Quantum Living Inc., a New York corporation.

PART I

Item 1. Business

History and Overview

Antiaging Quantum Living Inc., previously known as Achison Inc., (the “Company”) is a New York corporation formed on December 29, 2014. Our current principal executive office is 135-27 38th Ave #388, Flushing, NY 11354, New York. Tel: 929-990-3255.

On July 1, 2019 Lansdale Inc, the principal stockholder of the Company (“Seller”) and controlled by the Company’s prior President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”), pursuant to which, among other things, Seller agreed to sell to the Buyer, and the Buyer agreed to purchase from Seller, a total of 9,000,000 shares of Class A Common Stock of the Company of record and beneficially by Seller. The Purchased Shares represented approximately 90% of the Company’s issued and outstanding shares of Class A Common Stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

Prior to the change of the management team, the Company was engaging in holding or trading securities in the US market, trading spot silver in Singapore’s market as well as to trade whisky in the UK market. The Company has changed its focus to operate online advertising business through www.dazhong368.com (the “Website”) in the New York area.

The Website was established by Mr. Zhang in 2014 which is mainly focused on customers in the Greater New York area. The Website advertises different markets for professional individuals or companies including real estate, services, accounting, legal and so forth. We charge certain fees from these advertisements posted on our Website. The Company expects to generate revenue from the online advertising business and we also seek other profitable business at the same time.

On March 21, 2023, Barry Wan entered into a stock purchase agreement acquiring control of 29,215,000 restricted shares of common stock of the Company, representing approximately 97.4% of the Company’s total issued and outstanding common stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the “transaction”).

On April 10, 2023, during the closing of the transaction, Barry Wan assigned all his shares to New Lite Ventures LLC (A.K.A. “New Living Ventures LLC”, “LLC”), a Delaware Limited Liability Company, with which Barry Wan is the sole member. The foregoing transaction resulted in a change of control of the Company, with LLC 97.4% of the Company’s outstanding Common Stock. Both before and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan was approved by Directors Resolution to act as the new Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board of Directors after Ms. Jing Wan resigned. The Company was renamed as Antiaging Quantum Living Inc. on June 14, 2023 by the new management. Along with the name change, the ticker symbol of the Company was modified to “AAQL”. The Company plans to continue its existing operations through its website at www.dazhong368.com, which, since 2014, has provided online advertising to different individuals or companies operating in real estate, accounting, legal and other professional services in the New York City area. Its revenues are generated from advertising fees.

On October 4, 2023, the Board of Directors of the Company approved the appointment of PWN LLP to be the new independent registered public accounting firm, as a result of the competitive selection process to determine the independent registered public accounting firm for the financial period ending September 30, 2023. The action effectively dismissed Simon & Edward, LLP as the Company’s independent registered public accounting firm as of October 4, 2023

On December 29, 2023, the Board of Directors of the Company adopted a resolution to expand its operations into the global market, specifically targeting the Asia-Pacific and Chinese markets. In line with this expansion, the Company established multiple business entities as follows: AAQL Inc. (“BVI Holding”), a British Virgin Islands Company wholly owned by the Company, AAQL HK Limited (“Hong Kong Holding”), a wholly-owned subsidiary of BVI Holding, Antiaging Doctor Hangzhou Holding LTD (“Dao Ling Doctor Hangzhou”), a wholly-owned subsidiary of Hong Kong Holding, Dao Ling Doctor (Zhejiang) Health Management Limited (“Dao Ling Doctor Zhejiang”), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou, and Dao Ling Doctor (Huzhou) Health Management Limited ( “Dao Ling Doctor Huzhou”), a wholly-owned subsidiary of Dao Ling Doctor Hangzhou. Consequently, this transition eventually shifted the Company from being categorized as a shell company under 17 CFR § 240.12b-2 to an entity actively conducting business operations through its subsidiaries.

Dao Ling Doctor Zhejiang’s primary business involves providing professional technical development and maintenance services to distributors of the “Dao Ling Doctor” brand, and collecting technical service fees.

Dao Ling Doctor Huzhou’s primary business involves providing health consulting services (excluding diagnosis and treatment services), network and information security software development and big data services, and other services.

On June 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved, by written consent, an amendment to its Certificate of Incorporation of the Company to increase in the number of authorized shares of common stock of the Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of common stock, par value $0.00001 per share (the “Authorized Capital Increase”). Upon the effectiveness of the Authorized Capital Increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares.

On June 6, 2024, the Certificate of Amendment to the Certificate of Incorporation was filed with New York State Department effectuating the Authorized Capital Increase.

Products and Services

Our current services will focus on website development, maintenance and online business advertisement. Meanwhile, we will also search for different business opportunities to be acquired by the Company.

We will continue to improve our online platform in order to expand our customer base. The potential customer resource of our online advertising platform will be mainly from professional individuals and small companies that will use our platform to promote their services or products to their end-users.

Strategy

Our strategy is to target the small to medium-sized companies as well as the professional individuals that will use our Website to promote their products or services. Except to build up a customized ID card introduction for each of our customers, we will also help our customers to maintain their content information posted under their ID card introduction. We hope this one-stop service will better serve our potential customers.

Competitive Conditions

The online advertising industry is highly competitive, rapidly evolving and subject to constant technological change and intense marketing by providers with similar products and services.

A few of our competitors have substantially greater financial, technical and marketing resources, larger customer bases, longer operating histories, greater name recognition and more established relationships in the industry than we have. As a result, certain of these competitors may be able to adopt more aggressive pricing policies that could hinder our ability to market our services. We believe that our key competitive advantages are our ability to deliver reliable, high quality service in a cost-effective manner. We cannot provide assurances, however, that these advantages will enable us to succeed against comparable service offerings from our competitors

Item 1A. Risk Factors

Not applicable to smaller reporting companies

Item 1B. Unresolved Staff Comments

None

Item 1C. Cybersecurity

As a smaller reporting company, we are not required to provide the information required by this Item.

Item 2. Properties

The Company owns no real estate. We currently maintain our corporate office at 135-27 38th Ave #388, Flushing, NY 11354, Tel: 929-990-3255. The President of the Company provides the office space at no cost.

Item 3. Legal Proceedings

None.

To the best of the Company’s knowledge and based on information currently available, the Company is not involved in any material claims or legal actions arising from the ordinary course of business. However, the Company is exposed to various risks and uncertainties that could potentially result in litigation or claims in the future. The Company continuously evaluates these contingencies and will adjust its disclosures as necessary.

Item 4. Mine Safety Disclosures

Not Applicable.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

There has only been limited trading for the Company’s Class A common stock since it began trading on October 19, 2021. There is no assurance that an active trading market will ever develop or, if such a market does develop, that it will continue. The Securities and Exchange Commission has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for purposes relevant to the Company, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (i) that a broker or dealer approve a person’s account for transactions in penny stocks and (ii) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to approve a person’s account for transactions in penny stocks, the broker or dealer must (i) obtain financial information and investment experience and objectives of the person and (ii) make a reasonable determination that the transactions in penny stocks are suitable for that person and that person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prepared by the Commission relating to the penny stock market, which, in highlight form, (i) sets forth the basis on which the broker or dealer made the suitability determination and (ii) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading, and about commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

Because of these regulations, broker-dealers may encounter difficulties in their attempt to buy or sell shares of our common stock, which may affect the ability of our shareholders to sell their shares in the secondary market and have the effect of reducing the level of trading activity in the secondary market. These additional sales practice and disclosure requirements could impede the sale of our common stock in the market place. In addition, the liquidity for our common stock may be decreased, with a corresponding decrease in the price of our common stock. Our shares are likely to be subject to such penny stock rules for the foreseeable future.

On June 3, 2021, our Class A common stock was listed for quotation on the OTC Markets under the symbol “ACHN”. The OTC Markets is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities. The OTC Markets securities are traded by a community of market makers that enter quotes and trade reports. This market is limited in comparison to the national stock exchanges and any prices quoted may not be a reliable indication of the value of our common stock.

In 2023, following the name change, the Company underwent Corporate Actions to change its symbol from “ACHN” to “AAQL”, effective September 26, 2023.

The following table sets forth, for each of the quarterly periods indicated, the high and low sales prices of our common stock, as reported on the OTC Markets.

Year 2024	Low		High
January 1 through March 31, 2024	$	0.53	$	0.99
April 1 through June 30, 2024	$	0.54	$	0.87
July 1 through September 30, 2024	$	0.51	$	1.00
October 1 through December 31, 2024	$	0.70	$	1.06

Year 2025	Low		High
January 1 through March 31, 2025	$	0.31	$	1.00
April 1 through June 29, 2025	$	0.30	$	1.00

Holders

There are approximately 36 holders of the Company’s Class A Common Stock. This figure does not include holders of shares registered in “street name” or persons, partnerships, associates, corporations or other entities identified in security position listings maintained by depositories.

Dividends

We have not declared any cash dividends on our common stock since our inception and do not anticipate paying any dividends in the foreseeable future. We plan to retain future earnings, if any, for use in our business. Any decisions as to future payments of dividends will depend on our earnings and financial position and such other facts, as the Board of Directors deems relevant.

Securities Authorized under Equity Compensation Plans

We do not have any equity compensation plans.

Common Stock Currently Outstanding

As of March 31, 2026, 34,275,340 shares of Class A Common Stock were issued and outstanding. No shares of Class B Common Stock, Class C Common Stock, Class D Common Stock or Class E Common Stock were issued and outstanding.

Repurchases of Equity Securities

None

Reports to Stockholders

We are currently subject to the information and reporting requirements of the Securities Exchange Act of 1934 and will continue to file periodic reports, and other information with the SEC.

Transfer Agent

Dynamic Stock Transfer, Inc., 15233 Ventura Blvd., Suite 710, Sherman Oaks, CA, 91403 is the registrar and transfer agent for the Company’s common stock.

Recent Sales of Unregistered Securities

On November 25, 2025, the Company entered into four separate Assignment and Amendment of Promissory Note agreements with respect to certain outstanding promissory notes. Pursuant to these agreements, the applicable original noteholders assigned their rights and interests in the notes to Atlantic Equity Holdings Inc. or Empire Street Capital Inc., with the Company’s consent. Immediately upon each assignment, the applicable amended promissory note automatically converted into shares of Class A Common Stock at a fixed conversion price of $0.30 per share.

On November 25, 2025, the Company’s majority stockholder approved, by written consent, the issuance of all shares of Class A Common Stock issued in connection with the Assignment and Amendment of Promissory Note agreements.

No shares were issued at the time the original promissory notes were issued in December 2024 because those notes were unsecured, non-interest-bearing loan obligations and did not contain conversion features at issuance.

The foregoing issuances were made without registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) and Rule 506(b) of Regulation D, as the transactions did not involve any general solicitation and the purchasers were accredited investors. No underwriters participated in, or received any commissions or discounts from, these issuances.

Additional Information

We are a reporting issuer, subject to the Securities Exchange Act of 1934. Our Quarterly Reports, Annual Reports, and other filings can be obtained from the SEC’s Public Reference Room at 100 F Street, NE., Washington, DC 20549, on official business days during the hours of 10 a.m. to 3 p.m. You may also obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. The Commission maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Commission at http://www.sec.gov.

Item 6. Selected Financial Data

Not required under Regulation S-K for “smaller reporting companies.”

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our results of operations and cash flows for the years ended March 31, 2026 and 2025, and financial conditions as of March 31, 2026, and 2025 should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this Form 10-K.

Overview

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc., the principal stockholder of the Company (“Seller”) and an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc., (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company on the same date.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of Class A common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement, Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the purchased shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Class A common stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its Class A common stock outstanding.

The change in control with respect to the Company was effectuated to better reflect its new business direction, with the intention of acquiring businesses involved in healthcare management and insurance services.

In line with this expansion, the Company established AAQL Inc. AAQL HK Limited Dao Ling Doctor Hangzhou, Dao Ling Doctor Zhejiang, and Dao Ling Doctor Huzhou entities.

On July 25, 2024, the Board of Directors of the Company approved the appointment of J&S Associate PLT to be the new independent registered public accounting firm for the financial period ending June 30, 2024. This appointment addressed the vacancy created by the resignation of PWN LLP as the Company’s former independent registered public accounting firm.

On September 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved an amendment to its Certificate of Incorporation increase in the number of authorized shares of common stock of the Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of common stock, par value $0.00001 per share. Upon the effectiveness of the Authorized Capital Increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares. On the same day, the Certificate of Amendment to the Certificate of Incorporation of the Company was filed with New York State Department effectuating the Authorized Capital Increase.

During the fiscal year ended March 31, 2026, the Company initiated a strategic transition to shift its core business model away from third-party agency and technical platform operations to focus exclusively on the supply and distribution of proprietary brand health products and therapy services. Pursuant to board authorization in June 2025, the Company ceased its online platform technical operation support and maintenance services in staggered phases, concluding in September 2025 and January 2026.

We view this transition as a vital strategic pivot to enhance our brand value and establish long-term control over our product supply chain. However, this shift materially impacts our near-term consolidated financial results and the comparability of our historical financial statements to future periods.

Results of Operation for the years ended March 31, 2026 and 2025

	2026			2025			$ Changed			% Changed
Revenue		1,034,385			817,898			216,487			26.47	%
Cost of revenues		332,262			389,381			(57,119	)		-14.67	%
Gross profit		702,123			428,517			273,606			63.85	%
Gross margin		67.9	%		52.4	%
Selling, general and administrative expenses		1,537,524			1,218,476			319,048			26.18	%
Loss from operations		(835,401	)		(789,959	)		(45,442	)		5.75	%
Other income (loss)		14,415			69,550			(55,135	)		-79.27	%
Income tax expenses		16,660			-			16,660			100.0	%
Net loss		(837,646	)		(720,409	)		(117,237	)		16.27	%

During the years ended March 31, 2026 and 2025, the Company generated revenues of $1,034,385 and $817,898, respectively. Of this total, $711,607 (or 68.8%) in FY 2026 and $817,898 (or 100%) in FY 2025 was derived from our historical online platform technical operation support and maintenance services. The increase in revenue was primarily driven by the introduction of new therapy services and health/beauty product sales in FY 2026. As part of a strategic transition during the year, the Company ceased its historical online platform services to focus entirely on therapy services (which generated $141,828 in FY 2026) and proprietary health/beauty products (which generated $180,950 in FY 2026).

Cost of revenues was $332,262 and $389,381 for the years ended March 31, 2026 and 2025, respectively. Gross profit increased to $702,123 (gross margin of 67.9%) for the year ended March 31, 2026, as compared to gross profit of $428,517 (gross margin of 52.4%) for the year ended March 31, 2025. Gross margin improved from 52.4% to 67.9% primarily because our new therapy services and proprietary products carry higher profit margins compared to the labor-intensive technical operation support and maintenance services we provided in FY 2025.

The Company incurred operating expenses of $1,537,524 and $1,218,476 for the years ended March 31, 2026 and 2025, respectively. Operating expenses generally consists of rent and facility expenses, wages and salaries, legal and professional fees. The increase in operating expenses was mainly due to the increase in rental and facility costs.

For the year ended March 31, 2026, the Company had gain from extinguishment of liability of $10,771, in addition to interest income of $163 and subsidy income of $3,480, as compared to year ended March 31, 2025, the Company received renovation subsidy of $69,471 in addition to interest income of $79.

For the year ended March 31, 2026, our net loss was $837,646 compared to a net loss of $720,409 for the year ended March 31, 2025. The increase in net loss is mainly due to the increased operating expenses.

Historically, the delivery of our technical and platform services did not utilize dedicated, standalone operational teams or separate infrastructure. Instead, these services were supported by highly integrated, centralized corporate resources, including shared administrative personnel, centralized accounting and sales teams, and shared server infrastructure.

Following the cessation of the technical services, the Company has retained these shared personnel and infrastructural resources in their entirety. We have repurposed these assets to support the expansion and scaling of our continuing proprietary health products and therapy service lines. Consequently, while our consolidated revenues will materially decrease in the near term due to the loss of the technical service revenue, our general and administrative (G&A) expenses and overall operating cost structure will not experience a proportional decrease.

Because these centralized resources have been retained and absorbed by our continuing operations, and should expect near-term margin compression as our retained organizational overhead is now supported by a smaller, albeit strategically refocused, revenue base.

Equity and Capital Resources

As of March 31, 2026, we had an accumulated deficit of $2,247,358 and working capital deficit of $459,038, compared to accumulated deficit of $1,409,712 and a working capital of $132,689 as of March 31, 2025. The decrease in the working capital was primarily driven by a $460,000 increase in due to related parties.

Historically, the Company has financed its operations and alleviated working capital deficiencies primarily through advances from a principal shareholder and director. While there is no formal written commitment or binding agreement in place, the shareholder has historically provided necessary funding and has indicated the intent to continue providing financial support to fund the Company’s operations and meet its obligations as they become due.

Promissory Notes and November 2025 Assignments and Amendments

During fiscal 2025 and continuing into fiscal 2026, the Company funded a portion of its operations through the issuance of several promissory notes to multiple lenders. These included: (i) a note issued to Barry Wan in the principal amount of $428,789.50; (ii) a note issued to New Lite Ventures LLC in the principal amount of $29,571.00; (iii) two notes originally issued by the Company’s PRC subsidiaries, Antiaging Doctor Hangzhou Holding Ltd. and Dao Ling Doctor (Zhejiang) Health Management Limited, to Hemeihui E-Commerce Co., Ltd., in the principal amounts of $538,568.00 and $287,174.00, respectively; and (iv) a note issued to Tairan Baohe Insurance Sales Co., Ltd. in the principal amount of $383,598.00. The Tairan Baohe note was subsequently repaid in full and is no longer outstanding.

On November 25, 2025, the Company entered into four separate Assignment and Amendment of Promissory Note agreements with respect to the outstanding notes other than the repaid Tairan Baohe note. Under these agreements, each applicable noteholder assigned its rights and interests in the notes to either Atlantic Equity Holdings Inc. or Empire Street Capital Inc., and the notes were amended to provide for the automatic conversion of the outstanding principal balances into shares of the Company’s Class A Common Stock at a fixed conversion price of $0.30 per share. No additional proceeds were received by the Company in connection with these amendments, assignments, or conversions. Upon the issuance of the conversion shares, the applicable notes were deemed fully satisfied and extinguished.

The Company’s net loss was partially offset by non-cash expenses which primarily included $134,792 in depreciation and amortization, and $332,320 in amortization related to right-of-use (ROU) assets associated with leased office and retail spaces and leasehold improvements. Operating cash activities was further impacted by an $216,624 increase in inventories and a $92,753 increase in advances to suppliers, which were partially offset by a $317,479 increase in accounts payables and accrued expense, resulting in net cash used in operating activities for the years ended March 31, 2026.

During the years ended March 31, 2026 and 2025, the Company purchased fixed assets and intangible assets totaling $162,434 and $63,345, respectively.

During the years ended March 31, 2026 and 2025, the Company received advances of $460,000 and $364,303 from related parties for working capital purposes, which shareholders are prepared to provide additional funding as needed. The Company also borrowed $nil and $803,734 from an unrelated third party during the years ended March 31, 2026 and 2025, respectively.

On December 31, 2024, a total of $1,284,103 debt owed to related party and third party were converted into long-term notes payable, representing a non-cash financing activity. On March 31, 2025, the Company entered into Tripartite Debt Assignment Agreements with Mr. Barry Wan (a related party) and the unrelated third-party original lender, pursuant to which certain loans and notes totaling $1,216,440 were legally assigned to Mr. Wan.

As of March 31, 2026, we held approximately $503,486 in cash and cash equivalents. Our liabilities are primarily funded by shareholder loans and unrelated parties’ loans, which do not require immediate repayment. Operations are continuing as usual, and management is committed to implementing expense control measures in the near term to support liquidity.

Going Concern Assessment

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern. These adverse conditions are negative financial trends, specifically cash outflow from operating activities, operating losses, accumulated deficit and other adverse key financial ratios.

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations and execute the business plan of the Company in order to meet its operating needs on a timely basis. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions included in footnote 2 of our financial statements is critical to an understanding of our financial statements.

Revenue Recognition

Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The Company determines revenue recognition by applying the following steps: 1) identification of the contract, or contracts, with a customer; 2) identification of the performance obligations in the contract; 3) determination of the transaction price; 4) allocation of the transaction price to the performance obligations in the contract; and 5) recognition of revenue when, or as, we satisfy a performance obligation.

Sales of goods

The Company generates revenue from the sale of health and beauty products, dietary supplements, and proprietary branded health foods. Goods are sold directly to consumers through the Company’s mobile application (“App”) and physical retail stores, as well as distributed wholesale to third-party e-commerce platforms and partners. In January 2026, the Company began transitioning its business model to become a primary product supplier of proprietary brands to enhance its control over the health and wellness supply chain.

A formal contract is established when a customer places an order. The Company’s single performance obligation is the delivery of the ordered goods. The transaction price is generally fixed at the time of the order. Revenue is recognized at a point in time when the goods are delivered to (or physically purchased at) retail stores, drop-shipped, and accepted by the customer, as control transfers at that time.

The Company’s policy allows for product returns, which are treated as variable consideration. Provisions for estimated sales returns are assessed and adjusted at the end of each reporting period based on historical return rates and experience, which are generally immaterial. The Company records contract liabilities, such as customer advances, when payments are received prior to the delivery and acceptance of goods.

Offline physical therapy services

The Company provides offline physical therapy and related health services through its physical retail stores. Customers may purchase these services on a single-use (pay-on-demand) basis or through multi-session package deals that are valid for a one-year period. A formal contract is established upon payment.

For single-use services, the Company has a single performance obligation to provide the therapy session. Revenue is recognized at a point in time when the service is rendered to the customer.

For multi-session package deals, the Company has a stand-ready obligation to provide services over the one-year validity period. Payments received in advance are initially recorded as contract liabilities (customer advances). Revenue is recognized over time as the services are utilized by the customer.

During the systems transition period for the year ended March 31, 2026, precise customer-level usage tracking was limited. Consequently, management utilized a critical accounting estimate to determine the proportional performance of these obligations based on a sample of available historical usage records applied to cohorts of contracts grouped by payment date. Management applies a constraint to these estimates to ensure it is highly probable that a significant reversal of cumulative revenue recognized will not occur. Revenue is recognized ratably based on this constrained estimate, with any remaining unconstrained balance recognized when the rights legally expire at the end of the one-year period. Changes to these estimation methods could materially impact the timing of revenue recognition.

Online platform technical operation support and maintenance services

Prior to January 2026, the Company provided technical operation support and maintenance services for online platforms, ensuring platform functionality, continuous availability, and technical support for end-users.

Revenue from these services was recognized ratably over each service period as the services were rendered, or upon completion of the service, depending on the nature of the arrangement. Billing frequency varied (e.g., weekly, monthly, quarterly, or upon completion) as specified in the respective contracts. Service fees were determined based on contract terms and structured as fixed fees, milestone-based pricing, or as a percentage of gross transaction value (GTV) generated from the customer’s e-commerce platform. Each billing period or completed service cycle represented a distinct performance obligation, with revenue recognized upon completion and invoicing. The major direct cost of providing these services was wages and salaries. In instances where payments were received in advance, they were recorded as contract liabilities (deferred revenue) until the services were delivered.

Effective January 2026, the Company formally ceased providing these technical operation support and maintenance services. Because these services were supported by highly integrated, centralized corporate resources that have been retained by the Company, the cessation of this service line does not qualify for presentation as a discontinued operation.

Principal vs. Agent Consideration

For each revenue stream, the Company is a principal because it controls the specified goods or services before they are transferred to the customer. As a principal, the Company is primarily responsible for fulfilling the contractual obligations, has discretion in establishing the price, and bears the risk of inventory or service provision until completion; therefore, revenue is recognized on a gross basis for each active revenue stream.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Not required under Regulation S-K for “smaller reporting companies.”

Item 8. Financial Statements and Supplementary Data

Our audited financial statements are set forth in this Annual Report beginning on page F-2.

ANTIAGING QUANTUM LIVING INC.

INDEX TO FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm (PCAOB ID NO: 6743)		F-2

Consolidated Balance Sheets As of March 31, 2026 and 2025		F-3

Consolidated Statements of Operations and Comprehensive Income For the years ended March 31, 2026 and 2025		F-4

Consolidated Statements of Changes in Shareholders’ Deficit For the years ended March 31, 2026 and 2025		F-5

Consolidated Statements of Cash Flows For the years ended March 31, 2026 and 2025		F-6

Notes to Financial Statements		F-7

F-1

J&S ASSOCIATE PLT

202206000037 (LLP0033395-LCA) & AF002380

(Registered with PCAOB and MIA)

B-11-14, Megan Avenue II

12,Jalan Yap Kwan Seng, 50450, Kuala Lumpur, Malaysia

Tel: +603-4813 9469
Email : info@jns-associate.com
Website : jns-associate.com

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Shareholders of

Antiaging Quantum Living Inc.

Opinion on the Financial Statement

We have audited the accompanying consolidated balance sheets of Antiaging Quantum Living Inc. and its subsidiary (collectively the ‘Company’) as of March 31, 2026 and 2025, and the related consolidated statements of income and comprehensive income, consolidated statements of changes in shareholders’ equity, and consolidated statements of cash flows for the years ended March 31, 2026 and 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of March 31, 2026 and 2025, and the results of its operations and its cash flows for the years ended March 31, 2026 and 2025, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/J&S Associate PLT
Certified Public Accountants
PCAOB No: 6743

We have served as the Company’s auditor since 2025.

Kuala Lumpur, Malaysia

July 14, 2026

F-2

ANTIAGING QUANTUM LIVING INC.

Consolidated Balance Sheets

As of March 31, 2026 and 2025

	March 31,			March 31,
	2026			2025
ASSETS
Current Assets
Cash and cash equivalents	$	503,486		$	370,549
Accounts receivable, net		30,000			85,788
Inventories, net		219,036			-
Advances to suppliers		231,523			132,123
Other receivables and current assets		229,937			222,055
Total Current Assets		1,213,982			810,515
Non-Current Assets
Property and equipment, net		148,215			120,769
Intangible assets, net		12,806			13,551
Operating lease right of use asset, net		347,682			644,515
Total Non-Current Assets		508,703			778,835
Total Assets		1,722,685			1,589,350

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses		389,582			50,244
Other payables		153,364			49,097
Due to related parties		980,000			520,000
Taxes payable		1,297			3,960
Contract liabilities		97,605			8,475
Operating lease liabilities - current portion		51,172			46,050
Total Current Liabilities		1,673,020			677,826
Non-Current Liabilities
Operating lease liabilities - non-current		319,621			366,740
Long term notes and loans payable-related party		-			1,674,801
Long term loans payable		405,915			-
Total Non-Current Liabilities		725,536			2,041,541
Total Liabilities		2,398,556			2,719,367

Commitments and Contingencies					-

Shareholders’ Equity
Class A Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; 34,275,340 and 29,995,000 shares issued and outstanding at March 31, 2026 and 2025		30,423			29,995
Class B Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and 2025		-			-
Class C Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and 2025		-			-
Class D Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and 2025		-			-
Class E Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and 2025		-			-
Common stock, value		-			-
Additional paid-in capital		1,527,204			243,530
Accumulated deficit		(2,247,358	)		(1,409,712	)
Accumulated other comprehensive (loss) income		13,860			6,170
Total Shareholders’ Deficit		(675,871	)		(1,130,017	)
Total Liabilities and Shareholders’ Deficit	$	1,722,685		$	1,589,350

The accompanying notes are an integral part of these consolidated financial statements.

F-3

ANTIAGING QUANTUM LIVING INC.

Consolidated Statements of Operations and Comprehensive Income

For the years ended March 31, 2026 and 2025


	Years ended
	March 31,			March 31,
	2026			2025
Revenues, net	$	1,034,385		$	817,898
Cost of revenues		332,262			389,381
Gross profit		702,123			428,517

Operating expenses:
Selling and marketing expenses		160,731			158,136
General and administrative expenses		1,376,793			1,060,340
Total operating expenses		1,537,524			1,218,476

Loss from operations		(835,401	)		(789,959	)

Other income:
Interest income		163			79
Other income		14,252			69,471
Total other income		14,415			69,550

Loss before income tax		(820,986	)		(720,409	)

Income tax expense		16,660			-
Net loss	$	(837,646	)	$	(720,409	)

Weighted average shares outstanding
Basic and diluted		31,484,324			29,995,000

Loss per share
Basic and diluted	$	(0.0266	)	$	(0.0240	)

Comprehensive loss:
Net loss	$	(837,646	)	$	(720,409	)
Other comprehensive loss:
Foreign currency translation adjustment		7,690			3,562
Total comprehensive loss	$	(829,956	)	$	(716,847	)

The accompanying notes are an integral part of these consolidated financial statements.

F-4

ANTIAGING QUANTUM LIVING INC.

Consolidated Statements of Changes in Shareholders’ Deficit

For the years ended March 31, 2026 and 2025

	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive Income/(Loss)		Total
	Class A Common stock				Additional					Accumulated other
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive Income (Loss)		Total

Balance at March 31, 2025		29,995,000	$	29,995	$	243,530	$	(1,409,712	)	$	6,170	$	(1,130,017	)
Conversion of notes payable to common stock		4,280,340		428		1,283,674		-			-		1,284,102
Net loss		-		-		-		(837,646	)		-		(837,646	)
Foreign currency translation adjustment		-		-		-		-			7,690		7,690
Balance at March 31, 2026		34,275,340	$	30,423	$	1,527,204	$	(2,247,358	)	$	13,860	$	(675,871	)

Balance at March 31, 2024		29,995,000	$	29,995	$	243,530	$	(689,303	)	$	2,608	$	(413,170	)
Balance		29,995,000	$	29,995	$	243,530	$	(689,303	)	$	2,608	$	(413,170	)
Net loss		-		-		-		(720,409	)		-		(720,409	)
Foreign currency translation adjustment		-		-		-		-			3,562		3,562
Balance at March 31, 2025		29,995,000	$	29,995	$	243,530	$	(1,409,712	)	$	6,170	$	(1,130,017	)
Balance		29,995,000	$	29,995	$	243,530	$	(1,409,712	)	$	6,170	$	(1,130,017	)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

ANTIAGING QUANTUM LIVING INC.

Consolidated Statements of Cash Flows

For the years ended March 31, 2026 and 2025

	2026			2025
	Years ended
	March 31,			March 31,
	2026			2025
Operating activities
Net loss	$	(837,646	)	$	(720,409	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense		134,792			144,271
Amortization of operating lease ROU assets		332,320			330,671
Write-off assets		-			27,000
Impairment loss on property and equipment		4,007			-
Changes in assets and liabilities
Decrease (increase) in accounts receivable		57,657			(84,267	)
Increase in inventories		(216,624	)		-
Increase in advances to suppliers		(92,753	)		(132,123	)
Decrease (increase) in prepaid expenses		15,061			(65,489	)
Increase in other receivables and current assets		(14,595	)		(96,097	)
Increase (decrease) in accounts payable and accrued expenses		317,479			(4,428	)
Increase in other payables		112,507			34,850
Increase in contract liabilities		89,130			4,130
Decrease in operating lease liabilities		(72,360	)		(338,389	)
Net cash used in operating activities		(171,025	)		(900,280	)

Investing activities
Purchase of fixed assets		(162,434	)		(49,488	)
Purchase of intangible assets		-			(13,857	)
Net cash used in investing activities		(162,434	)		(63,345	)

Financing activities
Proceeds from notes payables		-			803,734
Proceeds from related party payables		460,000			364,303
Net cash provided by financing activities		460,000			1,168,037

Net increase of cash and cash equivalents		126,541			204,412
Effect of foreign currency translation on cash and cash equivalents		6,396			(415	)
Cash and cash equivalents – beginning		370,549			166,552
Cash and cash equivalents – ending	$	503,486		$	370,549

Supplementary cash flow information:
Interest paid	$	-		$	-
Income taxes paid	$	16,660		$	-

Non-cash financing and investing activities:
Recognized ROU assets through lease liabilities	$	-		$	424,790
Conversion of loan payable to promissory note payable	$	-		$	1,284,103
Debt assignment to related party	$	-		$	1,216,440
Conversion of notes payable to common stock	$	1,284,102		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-6

ANTIAGING QUANTUM LIVING INC

NOTES TO FINANCIAL STATEMENTS

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Antiaging Quantum Living Inc. (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc, the principal stockholder of the Company (“Seller”) an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock (the “Common Stock”) from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement (“SPA”), Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the Purchased Shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Common Stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

AAQL Inc. (“BVI Holding”) was incorporated under the Laws of the British Virgin Islands to function as a holding company responsible for managing all business operations outside of the United States.

AAQL HK Limited (“Hong Kong Holding”) was incorporated under the Laws of Hong Kong as a wholly-owned subsidiary of the BVI Holding. Hong Kong Holding’s primary role is to act as a holding company overseeing business activities exclusively within the Asia-Pacific markets.

Antiaging Doctor Hangzhou Holding LTD (“Dao Ling Doctor Hangzhou”) was incorporated as a wholly-owned subsidiary of Hong Kong Holding on November 13, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Xiaoshan District, Hangzhou, Zhejiang Province.

Dao Ling Doctor (Zhejiang) Health Management Limited (“Dao Ling Doctor Zhejiang”) was incorporated as a wholly-owned subsidiary of Dao Ling Doctor Hangzhou on November 30, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Hangzhou, Zhejiang Province.

Dao Ling Doctor (Huzhou) Health Management Limited (“Dao Ling Doctor Huzhou”) was incorporated as a wholly-owned subsidiary of Dao Ling Doctor Hangzhou on December 6, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Huzhou, Zhejiang Province.

Anti-Aging Care LLC (“Anti-Aging Care”) was incorporated as a wholly-owned subsidiary of Antiaging Quantum Living Inc. on October 21, 2024 under the laws of New York.

The subsidiaries’ business includes e-commerce platform development and management, personalized marketing strategies, and brand licensing. It also provides technical support and maintenance for distributors, along with health consulting (excluding diagnosis and treatment), network security software development, and big data services. Through these integrated offerings, the group enhances the market presence and operational efficiency of the ‘Dao Ling Doctor’ brand.”

Antiaging Quantum Living Inc. and its subsidiaries are collectively referred to as the “Company”.

F-7

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and include the assets, liabilities, revenues, expenses and cash flows of all subsidiaries. All significant inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

Use of Estimates

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”).

The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Actual results may differ from those estimates and assumptions.

Significant estimates and assumptions made by management include, but are not limited to, the recognition of revenue (including the portfolio approach used for estimating the proportional performance and breakage of multi-session service packages), the allowance for expected credit losses, the valuation of lease right-of-use assets and lease liabilities, and the valuation allowance for deferred tax assets.

Functional and presentation currency

The functional currency of the Company is the currency of the primary economic environment in which the Company operates which is Chinese Yuan (“RMB”). The RMB is not freely convertible into the US dollar and may be subject to PRC currency restrictions for payments, including the distributions of dividends or retained earnings to the Company by its subsidiaries or its variable interest entities.

Transactions in currencies other than the entity’s functional currency are recorded at the rates of exchange prevailing on the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at the end of the reporting periods. Exchange differences arising on the settlement of monetary items and on translation of monetary items at period-end are included in income statement of the period.

For the purpose of presenting these financial statements, the Company’s assets and liabilities are expressed in US$ at the exchange rate on the balance sheet date, stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rate during the period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss) in the stockholder’s equity (deficits) section of the balance sheets.

Exchange rate used for the translation as follows:

SCHEDULE OF EXCHANGE RATE

US$ to RMB	Period End		Average
March 31, 2026		6.8980		7.1019
March 31, 2025		7.2567		7.2163

Cash and Cash Equivalents

Cash and cash equivalents include cash in banks, bank deposits, and highly liquid investments with maturities of three months or less at the date of origination.

Accounts receivable, net

The Company records accounts receivable at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Inventories, net

Inventories consist of finished goods and are stated at the lower of cost or net realizable value. Cost is determined using the weighted average cost method. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company reviews the carrying value of inventory for obsolescence or slow-moving items periodically.

Advances to Suppliers

The Company occasionally makes advance payments to suppliers, contractors, and service providers to secure future deliveries of goods or completion of services. These advances are recorded as assets on the balance sheet and are reclassified to the appropriate expense or asset account (such as inventory, property and equipment, or repairs and maintenance) when the related goods are received or the services are rendered. These advances may include, but are not limited to, payments for inventory goods to be sold, deposits for services, or prepayments for capital improvements.

F-8

The Company periodically reviews the recoverability of advances to suppliers and establishes allowances for potential losses when necessary.

Other receivables and current assets

Other receivables and current assets consist primarily of prepaid expenses, advances, and refundable security deposits. These items are recorded at their original transaction amounts and are not discounted as the impact of discounting is not material to the consolidated financial statements. The Company evaluates the collectability of other receivables on a regular basis and establishes allowances for estimated credit losses, if necessary, in accordance with ASC 326.

Impairment of Other Assets

The Company has adopted Accounting Standards Codification subtopic 340-10, Other Assets (“ASC 340-10”). ASC 340-10 requires that prepaid expenses, deferred costs, and other capitalized expenditures be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates these assets for impairment periodically, or more frequently if events and circumstances warrant. Indicators of impairment may include contract cancellations, supplier bankruptcy, significant adverse changes in expected future benefits, or other factors reducing the asset’s recoverability.

The Company assesses recoverability based on the expected future benefits associated with the asset. If it is determined that the carrying value is no longer recoverable, the asset is written down to its net realizable value or zero if no recovery is expected. Impairment losses, if any, are recorded in the income statement as a charge to expense.

Impairment loss on advances to suppliers was $nil and $27,000 for the years ended March 31, 2026, and 2025, respectively.

Property and Equipment

Property and equipment are carried at cost net of accumulated depreciation. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset.

Property and equipment are depreciated on a straight-line basis over the following periods:

Leasehold improvements			2 years
Office furniture and equipment			3 years

Intangible assets

Intangible assets are carried at cost, net of accumulated amortization. Expenditures that enhance the functionality or extend the useful life of the intangible asset are capitalized. When intangible assets are retired or otherwise disposed of, the related gain or loss is included in operating income.

Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

Intangible assets are amortized on a straight-line basis over the following periods:

Patent

10 years

F-9

Impairment of Long-Lived Assets

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve breakeven operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

Impairment loss on property and equipment was $4,007 and $nil for the years ended March 31, 2026 and 2025, respectively.

Customer Advances

The Company records customer advances as liabilities when consideration is received in advance of the transfer of goods. These advances are recognized as revenue when the performance obligations associated with the advance are satisfied. These advances relate to the advance payment for orders of goods placed by the customers.

Leases

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.

The new leasing standard requires recognition of leases on the balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company does not recognize any leases with an initial term of 12 months or less on the balance sheets.

Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

Revenue Recognition

F-10

Sales of goods

Offline physical therapy services

For single-use services, the Company has a single performance obligation to provide the therapy session. Revenue is recognized at a point in time when the service is rendered to the customer.

For multi-session package deals, the Company has a stand-ready obligation to provide a specified number of therapy sessions over the one-year validity period. While each treatment session represents a distinct performance obligation, the Company utilizes a stand-ready obligation approach for financial reporting purposes during the systems transition period, as precise customer-level session tracking is currently limited. Payments received in advance are initially recorded as contract liabilities (customer advances). These advance payments are non-refundable. Revenue is recognized over time as the services are utilized by the customer.

Online platform technical operation support and maintenance services

Principal vs. Agent Consideration

F-11

Contract liabilities

The Company records contract liabilities when payments are received from customers, or the Company has an unconditional right to receive payments, prior to the satisfaction of the underlying performance obligations. Contract liabilities primarily consist of customer advances and deferred revenue associated with the following:

	●	Delivery of goods: Customer advances received prior to the delivery and acceptance of goods. These advances are recognized as revenue upon delivery and acceptance of the goods by customers.
	●	Multi-Session package deals: Payments received in advance of services rendered. These advances are initially recorded as contract liabilities and recognized as revenue as the individual sessions are delivered to the customer, or upon expiration of the one-year term.
	●	Online platform support services: Payments received in advance for online platform technical operation support and maintenance services. These amounts are recorded as deferred revenue and recognized as revenue over the period the support services are delivered.

Contract liability balances comprised of the following:

SCHEDULE OF CONTRACT LIABILITY BALANCES

	March 31, 2026			March 31, 2025
Opening balance	$	8,475		$	4,345
Payments received in advance		571,997			4,130
Revenues recognized		(482,867	)		-
Effect of exchange rate changes		-			-
Ending balance	$	97,605		$	8,475

The Company recognized revenue of $482,867 and $nil for the years ended March 31, 2026 and 2025, respectively, that was included in the contract liability balance at the beginning of each respective period.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses primarily consist of costs related to sales and marketing activities, administrative functions, and certain start-up costs.

Selling expenses include, but are not limited to, sales commissions, advertising costs, shipping and handling expenses, and costs associated with trade shows and promotional events. General and administrative expenses encompass salaries and benefits of employees not directly involved in production, rent, utilities, office supplies, legal and professional fees, other overhead costs, and certain start-up costs.

Start-up costs represent expenses associated with the establishment of new operations, including activities such as market research, product development, and initial marketing efforts.

The Company recognizes these expenses as incurred.

Defined Contribution Plans

The Company contributes to various government-mandated employee benefit plans in the People’s Republic of China, including pension, medical, unemployment, and housing provident funds. These contributions are made in accordance with local laws and regulations and are expensed as incurred. The Company’s obligations under these plans are limited to the amounts required to be contributed. For the years ended March 31, 2026 and 2025, the Company contributed approximately $68,666 and $165,510, respectively.

Income Taxes

The Company records income tax expense using the asset-and-liability method of accounting for deferred income taxes. Under this method, deferred taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that the deferred tax assets will not be realized.

F-12

When tax returns are filed, it is likely some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the statements of operations.

Earnings Per Share

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

As of March 31, 2026 and 2025, the Company does not have any potentially dilutive instrument.

Contingencies

Certain conditions may exist as of the date the financial statements are issued, which could result in a loss to the Company which will be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies arising from legal proceedings pending against the Company or unasserted claims that may rise from such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates it is probable a material loss will be incurred and the amount of the loss can be reasonably estimated, then the estimated loss is accrued in the Company’s financial statements. If the assessment indicates a material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

Fair Value Measurements

Fair value accounting establishes a framework for measuring fair value and expands disclosure about fair value measurements. Fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

●

Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

F-13

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

	●	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

The Company’s financial instruments consisted of cash, accounts receivables, accounts payable, contract liabilities and loan from shareholders. The estimated fair value of those balances approximates the carrying amount due to the short maturity of these instruments.

Credit Losses on Financial Instruments

The Company recognizes credit losses on financial instruments in accordance with Accounting Standards Codification (ASC) Topic 326, Financial Instruments – Credit Losses. The Company uses the Current Expected Credit Losses (CECL) model to estimate credit losses on financial assets measured at amortized cost, as well as certain off-balance sheet credit exposures.

Under the CECL model, the estimation of credit losses involves significant judgment and estimation uncertainty. Management exercises its judgment based on historical loss experience, current economic conditions, and reasonable and supportable forecasts. Changes in these factors could have a material impact on the estimated credit losses.

Segment Reporting

The Company follows the management approach for segment reporting in accordance with ASC 280, Segment Reporting. This approach is based on the way management organizes segments within the Company for making operating decisions and assessing performance. The Company’s Chief Executive Officer has been identified as the Chief Operating Decision Maker (“CODM”). As the Company’s underlying operations and cost structures are highly integrated, the CODM evaluates performance and allocates resources based on consolidated financial information. Accordingly, the Company has determined that it operates as a single reportable segment. Further details regarding the Company’s segment reporting are provided in Note 13.

Recent Accounting Pronouncements

Accounting Standards Update (“ASU”) 2025-06, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software modernizes the accounting for internal-use software by removing the requirement to identify discrete project development stages (such as the preliminary and application-development stages) and instead focuses on whether (1) management has authorized and committed to funding the project, (2) it is probable the project will be completed and the software will be used to perform its intended function, and (3) the entity has considered whether significant uncertainty exists in the development activities. The amendments are effective for fiscal years beginning after December 15, 2027, and for interim periods within those fiscal years. Early adoption is permitted. Entities may apply the amendments prospectively, retrospectively, or using a modified-prospective approach. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and related disclosures. The adoption is expected to primarily affect the timing of capitalizing certain software-development costs and may result in modifications to internal controls over capitalization judgments and related disclosures.

ASU 2025-05, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets introduces a practical expedient for measuring expected credit losses on current accounts receivable and current contract assets arising from contracts with customers under Topic 606. Under the expedient, entities may assume that conditions existing at the balance sheet date will remain unchanged over the asset’s remaining life when estimating expected credit losses. In addition, entities other than public business entities may elect, as an accounting policy, to consider subsequent cash collections that occur after the balance sheet date but before issuance of the financial statements when estimating expected credit losses. The amendments are effective for fiscal years beginning after December 15, 2025, and for interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively. The Company is currently evaluating the impact of ASU 2025-05 and does not expect the adoption to have a material impact on its consolidated financial statements. The Company expects to apply the practical expedient for qualifying current receivables and contract assets upon adoption.

ASU 2025-04, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Customer Share-Based Payment Awards, clarifies how entities account for share-based consideration payable to a customer. The ASU requires customer awards with vesting conditions tied to purchases to be treated as performance conditions, eliminates the forfeiture policy election, and states that the variable consideration constraint under ASC 606 does not apply to these awards. The standard is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements.

F-14

ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Accounting Acquirer in a Business Combination Involving a Variable Interest Entity, clarifies that when a business that is a VIE is acquired primarily with equity interests, the determination of the accounting acquirer should follow ASC 805 rather than defaulting to the primary beneficiary under ASC 810. The standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect a material impact upon adoption.

ASU 2025-02, Liabilities (Topic 405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 122, removes the guidance previously provided under SAB 121 and codified in ASC 405-S99. The amendment reflects the SEC’s rescission of SAB 121 and clarifies that custodians of crypto-assets should assess loss contingencies under ASC 450-20. This update is effective retrospectively for public business entities for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this standard to have a material impact on its financial statements.

ASU 2025-01, Presentation of Financial Statements (Topic 220): Clarifying the Effective Date of Disaggregation of Income Statement Expenses, confirms the effective date of ASU 2024-03 for public business entities. The guidance requires disaggregated expense information in the income statement and is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after that date. Early adoption is permitted. The Company is currently evaluating the impact of this standard.

Management does not believe that other recently issued but not yet adopted accounting pronouncements will have a material impact on the Company’s financial position, results of operations, or cash flows.

NOTE 3 – GOING CONCERN

The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has incurred net loss of $837,646 for the period ended March 31, 2026, had an accumulated deficit of $2,247,358, and working capital deficit of $459,038. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds from the majority shareholder and President of the Company to eliminate inefficiencies in order to meet its anticipated cash requirements. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.

NOTE 4 – ACCOUNTS RECEIVABLE, NET

Accounts receivable, net comprised of the following:

SCHEDULE OF ACCOUNTS RECEIVABLES

	March 31, 2026		March 31, 2025
Accounts receivable	$	30,000	$	85,788
Less: Allowance for credit loss		-		-
Total, net	$	30,000	$	85,788

There was no allowance for credit loss expenses for the years ended March 31, 2026 and 2025, respectively.

F-15

NOTE 5 – INVENTORIES, NET

Inventories, net comprised of the following:

SCHEDULE OF INVENTORIES, NET

	March 31, 2026			March 31, 2025
Finished goods	$	221,476		$	-
Finished goods in transit		7,610			-
Less: Obsolete/write-down inventory		(10,050	)		-
Total, net	$	219,036		$	-

Write-downs of inventories were $10,050 and $nil for the years ended March 31, 2026 and 2025, respectively.

NOTE 6 – OTHER RECEIVABLES AND CURRENT ASSETS

Other receivables and current assets, net comprised of the following:

	March 31, 2026		March 31, 2025
Other receivables and prepayments	$	170,131	$	165,740
Security deposits		57,995		56,315
Taxes recoverable		1,811
Less: Allowance for credit loss		-		-
Total, net	$	229,937	$	222,055

There was no allowance for credit loss expenses for the years ended March 31, 2026 and 2025, respectively.

NOTE 7 – PROPERTY AND EQUIPMENT, NET

Property and equipment, net comprised of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31, 2026			March 31, 2025
At Cost:
Leasehold improvements	$	375,463		$	248,614
Office furniture and equipment		67,349			22,716
Property plant and equipment , gross		67,349			22,716
Total cost		442,812			271,330
Less: Accumulated depreciation		(294,597	)		(150,561	)
Total, net	$	148,215		$	120,769

Depreciation expenses were $133,383 and $65,120 for the years ended March 31, 2026 and 2025, respectively.

Impairment losses were $4,007 and $nil for the years ended March 31, 2026 and 2025, respectively.

The Company did not dispose of any fixed assets for the years ended March 31, 2026 and 2025, respectively. Accordingly, no gain or loss on disposal of fixed assets was recognized.

F-16

NOTE 8 – INTANGIBLE ASSET, NET

Intangible asset, net comprised of the following:

SCHEDULE OF INTANGIBLE ASSET

	March 31, 2026			March 31, 2025
At Cost:
Patent	$	14,497		$	13,781
Total cost		14,497			13,781
Less: Accumulated amortization		(1,691	)		(230	)
Total, net	$	12,806		$	13,551

Amortization expenses were $1,409 and $230 for the years ended March 31, 2026 and 2025, respectively.

The amortization expenses for the succeeding five years as follows:

For the year ending March 31,
2027	$	1,408
2028		1,408
2029		1,408
2030		1,408
2031		1,408
Thereafter		5,766
Total	$	12,806

NOTE 9 – LOANS PAYABLE AND NOTES PAYABLE

Promissory Notes and Related Party Assignments

On December 31, 2024, the Company entered into promissory note agreements amending the terms of certain existing loan arrangements with a third-party outstanding balances of CNY 3,931,167 (approximately $538,568) and CNY 2,096,172 (approximately $287,174), including an extension of the maturity date to December 31, 2029. As a result of these amendments, the outstanding balances were reclassified from “Loans Payable” to “Notes Payable.” These notes were unsecured, non-interest-bearing, and had a stated maturity date of December 31, 2029.

On March 24, 2025, the Company borrowed CNY 2,800,000 (approximately $386,042) from another unrelated third party pursuant to a loan agreement. The loan was unsecured, non-interest-bearing, and had a stated maturity date of December 9, 2027.

On March 31, 2025, the Company entered into a tripartite debt assignment agreement (the “Tripartite Debt Assignment Agreement”) with a related party (Mr. Barry Wan), and the unrelated third-party lender mentioned above, pursuant to which the CNY 2,096,172 note, the CNY 2,800,000 loan, and the CNY 3,931,167 note were assigned to the related party under the same terms and conditions.

Debt Assignment and Conversion

On November 25, 2025, the Company cancelled the Tripartite Debt Assignment Agreement, and entered into new assignment and amendment agreements specifically for the CNY 2,096,172 and CNY 3,931,167 promissory notes (the “November Debt Assignment Agreements”). These notes were now assigned to third-party assignees and included a provision for the automatic conversion of the outstanding principal amounts into shares of the Company’s Class A common stock at a fixed conversion price.

Immediately upon the effectiveness of the amendments, the total principal of $1,284,102 from the promissory notes (one consolidated note consisting of the CNY 2,096,172 (approximately $538,568) and CNY 3,931,167 (approximately $287,174) balance, and a second consolidated note of $428,790 owing to Mr. Wan, the President of the Company, and the $29,571 owing to New Lite), as elaborated in Note 10, were automatically converted into 4,280,340 shares of the Company’s Class A common stock at $0.30 per share.

The CNY 2,800,000 loan was not included in the November Debt Assignment Agreements. Upon the cancellation of the Tripartite Debt Assignment Agreement, this loan remained outstanding under its original terms as an obligation to an unrelated third party. The loan is unsecured, non-interest-bearing, with a maturity date of December 9, 2027. As of March 31, 2026 and 2025, the Company has outstanding loans payable to the unrelated third party in the amount of $405,915 and $nil, respectively.

F-17

NOTE 10 – RELATED PARTY TRANSACTIONS

Due to related parties

Due to related parties comprised of the following:

SCHEDULE OF DUE TO RELATED PARTIES

March 31,

2026

March 31,
2025

Barry Wan (“Mr. Wan”)

980,000

520,000

Total

980,000

520,000

Amounts due to related parties were unsecured, non-interest-bearing, and due on demand.

Promissory Notes Payable and Loans Payable – Related Parties

The Company had long-term notes and loans payable-related parties (Mr. Wan, the Company’s President) of $nil and $1,674,801 as of March 31, 2026 and 2025, respectively. These arrangements were unsecured and non-interest-bearing, with $385,850 repayable on December 9, 2027, and the remaining $1,288,951 repayable on December 31, 2029.

Advances from Mr. Wan

During the years ended March 31, 2026, the Company received advances from Mr. Wan, the Company’s President, for working capital purposes. The outstanding amounts due to Mr. Wan were $980,000 and $520,000 as of March 31, 2026 and 2025, respectively. The advances were unsecured, non-interest-bearing, and due on demand.

On December 31, 2024, the Company formalized a promissory note agreement with Mr. Wan in the principal amount of $428,790, with a stated maturity date of December 31, 2029. As described in Note 9, this promissory note was subsequently assigned and converted into equity.

Debt Assignment to Mr. Wan

On March 31, 2025, the Company entered into a Tripartite Debt Assignment Agreement (“TDAA”) with Mr. Barry Wan (a related party) and the unrelated third-party original lender, pursuant to which the CNY 2,096,172 ($288,860) note, the CNY 2,800,000 ($385,850) loan, and the CNY 3,931,167 ($541,730) note; were legally assigned to Mr. Wan. Following the assignment, Mr. Wan became the holder of the obligations under the same terms and conditions. The outstanding long-term notes and loans payable-related party was $nil and $1,674,801 as of March 31, 2026 and 2025, respectively.

Subsequently, on November 25, 2025, the Company cancelled the TDAA and entered into new assignment and amendment agreements with respect to the outstanding promissory notes (under “November Debt Assignment Agreements”), pursuant to which the notes were assigned to third-party assignees and amended to provide for the automatic conversion of the outstanding principal amounts into shares of the Company’s Class A common stock at a fixed conversion price. Immediately upon the effectiveness of the amendments, the outstanding promissory notes were automatically converted into equity. The CNY 2,800,000 (approximately $385,850) loan was not included in the November Debt Assignment Agreements.

Advances from Tairan Baohe Insurance Sales Co., Ltd. (“Tairan”)

During the year ended March 31, 2025, the Company borrowed funds from Tairan Baohe Insurance Sales Co., Ltd. (“Tairan”), an entity in which Mr. Wan’s spouse is a shareholder, for working capital purposes. The loan was unsecured, non-interest-bearing, and due on demand. On December 31, 2024, the Company formalized a promissory note agreement in the principal amount of CNY 2,800,000 (approximately $383,598), with a stated maturity date of December 31, 2029.

On March 24, 2025, the Company repaid the full outstanding balance to Tairan. As a result, there were no amounts due to Tairan since then.

F-18

Advances from New Lite Ventures LLC (“New Lite”)

During the year ended March 31, 2025, the Company borrowed funds from New Lite Ventures LLC (“New Lite”), an entity controlled by Mr. Wan, for working capital purposes. The advances were unsecured, non-interest-bearing, and due on demand.

On December 31, 2024, the Company formalized a promissory note agreement with New Lite in the principal amount of $29,571, with a stated maturity date of December 31, 2029. On November 25, 2025, this promissory note was assigned to third-party assignees and converted into the Company’s Class A common stock.

NOTE 11 – INCOME TAX

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

United States

Net operation losses (“NOLs”) can carry forward indefinitely up to offset 80% of taxable income after CARES Act effect on December 31, 2017. As of March 31, 2026, deferred tax assets resulted from NOLs of approximately $302,000, respectively. The deferred tax asset has been fully reserved by a valuation allowance as the Company believes it is more likely than not that it will not realize the benefits.

Hong Kong

Companies incorporated in Hong Kong are subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is 16.5% on its taxable income generated from operations in Hong Kong. The Company did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Additionally, payments of dividends by the subsidiary incorporated in Hong Kong to the Company are not subject to any Hong Kong withholding tax.

PRC

Effective on January 1, 2008, the PRC Enterprise Income Tax Law, EIT Law, and Implementing Rules impose a unified enterprise income tax rate of 25% on all domestic-invested enterprises and foreign investment enterprises in PRC, unless they qualify under certain limited exceptions. As such, starting from January 1, 2008, the Company’s subsidiaries in PRC are subject to an enterprise income tax rate of 25%. NOLs can typically carried forward for a certain number of years (usually five years) to offset against future taxable income. As of March 31, 2026, the Company’s PRC operations had net operating losses which resulted in deferred tax assets of approximately $212,000. The deferred tax asset has been fully reserved for valuation allowance as the Company believes it is more likely than not that it will not realize the benefits.

Income Taxes Paid

For the years ended March 31, 2026, the Company paid income taxes of $16,635 in China and $25 in United States; and did not pay any income taxes domestically or in foreign jurisdictions for the years ended March 31, 2025.

The following table summarizes the taxable income (loss) before income taxes by jurisdiction:

	2026			2025
	Years ended March 31,
	2026			2025
United States	$	(650,153	)	$	(322,344	)
Hong Kong		-			-
China		(170,833	)		(398,065	)
Total	$	(820,986	)	$	(720,409	)

F-19

The following table summarizes a reconciliation of income tax expense for operations, calculated at the statutory income tax rate to total income tax expense (benefit):

	2026			2025
	Years ended March 31,
	2026			2025
Loss before income taxes	$	(820,986	)	$	(720,409	)
U.S. federal tax benefits (21%)		(136,532	)		(67,692	)
State tax benefit, net of federal benefits		(38,522	)		(19,099	)
PRC tax expenses (benefits) (25%)		(42,708	)		(99,516	)
Hong Kong tax benefits (16.5%)		-			-
Income tax benefits at statutory rate		(217,762	)		(186,307	)
Foreign tax rate differential		-			-
Change in valuation allowance		234,422			186,307
Other		-			-
Provision for income taxes expenses	$	16,660		$	-
Effective tax rate		(2.03	)%		0	%

NOTE 12 – SHAREHOLDERS’ EQUITY

The Company is authorized to issued 1,200,000,000 shares of Class A common stock, 1,200,000,000 Class B common stock, 1,200,000,000 Class C common stock, 1,200,000,000 Class D common stock, and 1,200,000,000 Class E common stock; all with a par value of $0.00001 per share.

As of March 31, 2026, the Company had 34,275,340 shares of Class A common stock issued and outstanding, and no shares of Class B, Class C, Class D, or Class E common stock were issued or outstanding.

On June 6, 2024, the Company amended its article with New York State to increase the authorized shares of common stock of the Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of common stock, par value $0.00001 per share (the “Authorized Capital Increase”). Upon the effectiveness of the authorized shares increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares.

During the years ended March 31, 2026, the Company issued 4,280,340 shares of Class A common stock upon the automatic conversion of promissory notes in accordance with the assignment and amendment agreements described in Note 9.

F-20

NOTE 13 – SEGMENT REPORTING

Segment Identification and Chief Operating Decision Maker

The Company operates and is managed as a 1single reportable segment. The Company has identified its Chief Executive Officer as the Chief Operating Decision Maker (“CODM”). The CODM evaluates performance and allocates resources based on the Company’s consolidated financial information, specifically utilizing consolidated net loss to make operating decisions. While the Company’s revenue streams across health and beauty products, technical support, and physical therapy which are distinct, the underlying operations, shared resources, and cost structures utilized to generate these revenues are highly integrated across the entire Company. Consequently, the CODM does not evaluate performance or allocate resources based on discrete financial information for the individual product or service lines.

In evaluating the Company’s single operating segment’s performance, the CODM is regularly provided with certain significant consolidated expenses. These primarily consist of cost of revenues, selling and marketing expenses, and general and administrative expenses. These costs represent significant segment expenses and are reported directly on the consolidated statements of operations. Other segment items include interest income, other income, and income tax expense.

Disaggregation of revenues

The Company disaggregates its revenue by major revenue streams, as the Company believes this disaggregation best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors.

SCHEDULE OF DISAGGREGATION OF REVENUES

	2026		2025
	Years ended March 31,
	2026		2025
Sales of goods (Health and beauty products)	$	180,950	$	-
Technical operation support and maintenance services		711,607		817,898
Offline physical therapy services		141,828		-
Total	$	1,034,385	$	817,898

Geographic Information

The Company’s revenues from external customers are attributed to geographic areas based on the location of the customer. Geographic information regarding the Company’s long-lived assets, which specifically consists primarily of property, plant, and equipment, and right-of-use assets, is based on physical location.

Revenue disaggregated by geographic area based on the location of the customers is as follows:

	2026		2025
	Years ended March 31,
	2026		2025
United States	$	322,778	$	-
China		711,607		817,898
Total	$	1,034,385	$	817,898

Long-lived assets by geographic area based on physical location is as follows:

	March 31, 2026		March 31, 2025
United States	$	492,831	$	423,993
China		3,066		341,291
Total, net	$	495,897	$	765,284

F-21

NOTE 14 – LEASES

The Company has various operating leases for its office space and retail space.

Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate the present value is incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each leases based primarily on its lease term.

Certain lease agreements may include renewal options that are exercisable at the Company’s discretion. The Company includes renewal periods in the lease term when it is reasonably certain that the renewal option will be exercised. For leases where the renewal is not reasonably certain, the extension options are excluded from the measurement of lease liabilities and right-of-use assets. The lease term used reflects only the non-cancellable period and any renewal options that the Company is reasonably certain to exercise.

Operating lease expenses were $412,352 and $330,671 for the years ended March 31, 2026 and 2025, respectively. The Company did not have short-term leases or subleases for the years ended March 31, 2026 and 2025. Lease payments are fixed and increase annually according to the stated terms in the lease agreements. The Company does not have any variable lease payments.

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

	Years ended March 31,
	2026			2025
Lease cost
Operating lease cost	$	412,352		$	330,671

Other Information
Cash paid for amounts included in the measurement of lease liabilities	$	72,360		$	338,389
Weighted average remaining lease term – operating leases (in years)		5.59			6.57
Average discount rate – operating lease		7.00	%		7.00	%

The supplemental balance sheet information related to leases is as follows:

	March 31, 2026		March 31, 2025
Operating leases
Right-of-use assets	$	347,682	$	644,515
Operating lease liabilities	$	370,793	$	412,790

The undiscounted future minimum lease payment schedule as follows:

For the year ending March 31,
2027	$	75,087
2028		77,340
2029		79,660
2030		82,050
2031		84,511
Thereafter		50,150
Total undiscounted lease payments		448,798
Less: interest		(78,005	)
Total lease liabilities	$	370,793

F-22

NOTE 15 – RISKS, COMMITMENTS AND CONTINGENCIES

Litigations and claims

To the best of the Company’s knowledge and based on information available as of March 31, 2026, the Company is not involved in any material claims or legal actions arising from the ordinary course of business. However, the Company is exposed to various risks and uncertainties that could potentially result in litigation or claims in the future. The Company continuously evaluates these contingencies and will adjust its disclosures as necessary.

Concentration Risks

For the years ended March 31, 2025, the Company derived 100% of its revenue from a single customer. Additionally, the Company has only one supplier for its primary service.

For the years ended March 31, 2026, the Company derived 50.6% and 18.4% of its revenue from two customers. Additionally, the Company purchased 74.1% from one supplier for its purchased goods.

The Company is economically dependent on limited customer and supplier, and the loss of its relationship with the customer and supplier could have a material adverse effect on its financial condition, results of operations, and cash flows.

NOTE 16 – SUBSEQUENT EVENTS

The Company evaluated all events and transactions that occurred after March 31, 2026 through the date the financial statements were issued. During this period, the Company did not identify any material recognized subsequent events that require adjustment to the accompanying financial statements.

On April 1, 2026, the Company entered into a 36-month operating lease agreement for office space in Hangzhou, PRC, which commenced on April 1, 2026. The total undiscounted base rent commitment over the lease term is approximately RMB 3.87 million, which includes an initial upfront payment of approximately RMB 2.46 million. In accordance with ASC 842, the Company expects to record a material operating lease right-of-use (“ROU”) asset and corresponding lease liability on its consolidated balance sheets.

F-23

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

On April 15, 2024, the Board of Directors of the Company received the formal notice that the former accountant PWN LLP (“PWN”), had made the decision to resign as the accountant effective April 15, 2024. On July 25, 2024, the Board of Directors of the Company voted unanimously to accept the resignation.

The reports of PWN on the Company’s consolidated financial statements for the fiscal year ended March 31, 2024 did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles. In connection with the audits of the Company’s consolidated financial statements for the fiscal year ended March 31, 2024, there were no disagreements with PWN on any matters of accounting principles or practices, financial statement disclosure or auditing scope and procedures which, if not resolved to the satisfaction of PWN, would have caused PWN to make reference to the matter in their report. There were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K) during the fiscal year ended March 31, 2024.

On July 25, 2024, J&S Associate PLT, (the “J&S”) was appointed as the Company’s independent registered public accounting firm for the financial period ending June 30, 2024, subject to completion of its standard client acceptance procedures.

During the two most recent fiscal years and the subsequent interim periods preceding the J&S’s appointment as independent accountant, the Company has not consulted with J&S with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that would have been rendered on the Company’s consolidated financial statements, or any other matters set forth in Item 304(a)(2)(i) or (ii) of Regulation S-K.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed with an objective of ensuring that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission, such as this Annual Report on Form 10-K, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission. Disclosure controls are also designed with an objective of ensuring that such information is accumulated and communicated to our management, including our chief executive officer, in order to allow timely consideration regarding required disclosures.

The evaluation of our disclosure controls by our principal executive officer included a review of the controls’ objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Annual Report. Our management, including our Chief Executive Officer, does not expect that disclosure controls can or will prevent or detect all errors and all fraud, if any. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that there were material weakness in our internal controls over Financial reporting as of March 31, 2026 and they were therefore not as effective as they could be to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The material weakness in our controls and procedure were lack of US GAAP knowledge and segregation duties. Management does not believe that any of these material weaknesses materially affected the results and accuracy of its financial statements. However, in view of this discovery of such weaknesses, management has begun a review to improve them.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company in accordance with as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the (i) effectiveness and efficiency of operations, (ii) reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and (iii) compliance with applicable laws and regulations. Our internal controls framework is based on the criteria set forth in the Internal Control - Integrated Framework that was issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management’s assessment of the effectiveness of the small business issuer’s internal control over financial reporting is as of the year ended March 31, 2026 . We believe that internal controls over financial reporting as set forth above shows material weaknesses and are not effective. We have identified material weaknesses considering the nature and extent of our current operations and any risks or errors in financial reporting under current operations.

This annual report does not include an attestation report of the company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report in this annual report.

Subsequent to the end of the period covered by this report, and in light of the weakness described above, management is in the process of designing and implementing improvements in its internal control over financial reporting and we currently plan to hire an independent third-party consultant to assist in identifying and determining the appropriate accounting procedures and controls to implement.

Item 9B. Other Information

Not applicable.

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The following table sets forth the names and ages of the current directors and executive officers of the Company, the principal offices and positions with the Company held by each person and the date such person became a director or executive officer of the Company. The executive officers of the Company are elected annually by the Board of Directors. The directors serve one-year terms until their successors are elected. The executive officers serve terms of one year or until their death, resignation or removal by the Board of Directors.

The following table sets forth information regarding the members of the Company’s board of directors and its executive officers:

Name	Age	Position	Year Commenced

Barry Wan	54	Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board of Directors	2023

Mr. Barry Wan was appointed as Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board of Directors of the Company on June 16, 2023.

Barry Wan obtained a Bachelor of Science in Mechanical Engineering from Hefei University of Technology, followed by a Master’s degree from Queens College, the City University of New York. Mr. Wan is an entrepreneur with experience in the science and technology, real estate, and insurance sectors in both the United States and China. In the 2000s, he established multiple companies in the United States, including REMAX People Realty, where he served as founder and Chief Executive Officer. In the 2010s, Mr. Wan expanded his entrepreneurial activities into China, including through businesses and projects involving e-commerce, healthcare-related services, and business consulting.

Term of office

All officers and directors listed above will remain in office until the next annual meeting of stockholders and until their successors have been duly elected and qualified, or until removed from office in accordance with the Company’s bylaws. Officers are appointed annually by the Board of Directors and serve at the discretion of the Board of Directors.

Director Independence

The Board of Directors consists of one member, Mr. Barry Wan, who does not meet the independence requirements of the Nasdaq Stock Market.

Committees and Terms

The Board of Directors has not established any standing committees. The Company does not currently have an audit committee, compensation committee, or nominating committee. The Company’s Board of Directors currently performs the functions that would otherwise be performed by such committees.

Code of Ethics

The Company has not adopted a code of ethics applicable to its principal executive officer and principal financial officer. The Company expects to evaluate the adoption of a code of ethics as its business and operations develop.

Corporate Governance

There have been no changes in any state law or other procedures by which security holders may recommend nominees to our board of directors. In addition to having no nominating committee for this purpose, we currently have no specific audit committee and no audit committee financial expert. Based on the fact that our current business affairs are simple, any such committees are excessive and beyond the scope of our business and needs.

Nominating Committee

We have not adopted any procedures by which security holders may recommend nominees to our board of directors.

Audit Committee and Audit Committee Financial Expert

We do not currently have an audit committee financial expert, nor do we have an audit committee. Our entire board of directors, which currently consists of Barry Wan, handles the functions that would otherwise be handled by an audit committee. We do not currently have the capital resources to pay director fees to a qualified independent expert who would be willing to serve on our board and who would be willing to act as an audit committee financial expert. As our business expands and as we appoint others to our board of directors, we expect that we will seek a qualified independent expert to become a member of our board of directors. Before retaining any such expert our board would make a determination as to whether such person is independent.

Item 11. Executive Compensation

During the three years ended March 31, 2026, 2025, and 2024, no salaries were paid to any officers or directors.

Executive compensation during the three years ended March 31, 2026, 2025, and 2024 were as follows:

Summary Compensation Table

Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Change in Pensions Value and Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Dingshan Zhang, Former Chief Executive Officer / Chief Financial Officer ⁽¹⁾	2026	-	-	-	-	-	-	-	-
	2025	-	-	-	-	-	-	-	-
	2024	-	-	-	-	-	-	-	-

Jing Wan, Former Chief Executive Officer / Chief Financial Officer ⁽²⁾	2026	-	-	-	-	-	-	-	-
	2025	-	-	-	-	-	-	-	-
	2024	-	-	-	-	-	-	-	-

Barry Wan, Chief Executive Officer / Chief Financial Officer ⁽³⁾	2026	-	-	-	-	-	-	-	-
	2025	-	-	-	-	-	-	-	-
	2024	-	-	-	-	-	-	-	-

	(1)	Mr. Zhang resigned as a Director, President, CEO and CFO of the Company on April 10, 2023.
	(2)	Ms. Wan resigned as a Director, President, CEO and CFO of the Company on June 16, 2023.
	(3)	Mr. Wan was appointed as a Director, President, CEO and CFO of the Company on June 16, 2023

Director Compensation

We do not currently pay any compensation to our directors, nor do we pay directors’ expenses in attending board meetings.

Employment Agreements

The Company has not entered into employment agreements with any of its employees or officers as of March 31, 2026.

Stock Option Plan

We do not have a stock option plan and we have not issued any warrants, options or other rights to acquire our securities. However, we may adopt an incentive and non-statutory stock option plan in the future.

Employee Pension, Profit Sharing or other Retirement Plans

We do not have a defined benefit, pension plan, profit sharing or other retirement plan, although we may adopt one or more of such plans in the future.

Item 12. Security ownership of certain beneficial owners and management

The following table sets forth, as of March 31, 2026, the number and percentage of outstanding shares of Class A Common Stock beneficially owned by: (i) each person known by the Company to beneficially own more than 5% of the Company’s outstanding Class A Common Stock; (ii) each director; (iii) each named executive officer; and (iv) all directors and executive officers as a group.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission. The percentage ownership set forth below is based on 34,275,340 shares of Class A Common Stock issued and outstanding as of March 31, 2026. Unless otherwise indicated, the principal address of each stockholder listed below is c/o Antiaging Quantum Living Inc., 135-27 38th Avenue, #388, Flushing, New York 11354.

Title of Class	Name and Address Of Beneficial Owner	Position		Amount and Nature Of Beneficial Ownership		Percent Of Class⁽¹⁾

Class A Common Stock	New Lite Ventures LLC A.K.A New Living Ventures LLC, 135-27 38th Ave #388 Flushing, NY 11354 ⁽²⁾⁽³⁾		-		29,215,000		85.24	%
Class A Common Stock	Barry Wan, 135-27 38th Avenue, #388, Flushing, NY 11354		Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board		29,215,000		85.24	%
Class A Common Stock	Atlantic Equity Holdings Inc., 8 The Green, Ste R, Dover, DE 19901				1,893,796		5.53	%
Class A Common Stock	Empire Street Capital Inc., 136-20 38th Avenue, Ste 3D, Flushing, NY 11354 Empire Street Capital Inc., 136-20 38th Avenue, Ste 3D, Flushing, NY 11354				2,386,544		6.96	%
Class A Common Stock	All directors and executive officers as a group, one person				29,215,000		85.24	%

(1) Based on 34,275,340 shares of Class A Common Stock issued and outstanding as of March 31, 2026.

(2) Mr. Barry Wan may be deemed to beneficially own the shares held by New Lite Ventures LLC, also known as New Living Ventures LLC, because he wholly owns and controls New Lite Ventures LLC. The shares reported for Mr. Wan and for all directors and executive officers as a group consist of the same shares held of record by New Lite Ventures LLC and should not be double-counted.

(3) Includes 1,893,796 shares issued to Atlantic Equity Holdings Inc. upon conversion of the notes originally issued to New Lite Ventures LLC and Antiaging Doctor Hangzhou Holding Ltd.

(4) Includes 2,386,544 shares issued to Empire Street Capital Inc. upon conversion of the notes originally issued to Barry Wan and Dao Ling Doctor (Zhejiang) Health Management Limited.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The Company has been provided office space by its President at no cost. The management determined that such cost is nominal and did not recognize the rent expense in its financial statements.

Related Party Transactions

In August 2019, the Company borrowed $71,000 from the Company’s former President, Mr. Dingshan Zhang. The loan was non-interest-bearing and originally matured in December 2021. During the year ended March 31, 2022, the Company repaid $17,000 to Mr. Zhang. In May 2021, the Company borrowed an additional $5,000 from Mr. Zhang. On December 29, 2021, the Company and Mr. Zhang verbally amended the loan agreement and extended the maturity date to December 31, 2023. During the year ended March 31, 2023, the Company received an additional loan in the amount of $24,300 from Mr. Zhang.

Upon consummation of the change of control transaction entered into on April 10, 2023, the balance of the $83,300 shareholder loan was waived by Mr. Zhang in its entirety, which was recognized as an equity transaction with the shareholder.

During the fiscal year ended March 31, 2025 and the fiscal year ended March 31, 2026, the Company received advances from Mr. Barry Wan, the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Chairman of the Board, for working capital purposes. Such advances were unsecured, non-interest-bearing, and due on demand. The outstanding balance of such advances was $980,000 and $520,000 as of March 31, 2026 and 2025, respectively.

In December 2024, the Company issued several unsecured, non-interest-bearing promissory notes, including: (i) a note in the principal amount of $428,789.50 issued to Mr. Barry Wan; (ii) a note in the principal amount of $29,571.00 issued to New Lite Ventures LLC, an entity wholly owned and controlled by Mr. Wan; (iii) two notes in the principal amounts of $287,174.00 and $538,568.00, respectively, issued by the Company’s PRC subsidiaries, Dao Ling Doctor (Zhejiang) Health Management Limited and Antiaging Doctor Hangzhou Holding Ltd., to Hemeihui E-Commerce Co., Ltd.; and (iv) a note in the principal amount of $383,598.00 issued to Tairan Baohe Insurance Sales Co., Ltd. None of these notes contained conversion features at the time of issuance.

The note issued to Tairan Baohe Insurance Sales Co., Ltd. was subsequently repaid in full and was not amended, assigned, or converted.

On November 25, 2025, the Company entered into four separate Assignment and Amendment of Promissory Note agreements with respect to the outstanding notes other than the repaid Tairan Baohe note. Pursuant to these agreements, each applicable original noteholder assigned its rights and interests in the applicable note to either Atlantic Equity Holdings Inc. or Empire Street Capital Inc., with the Company’s consent. Immediately upon each assignment, the applicable amended promissory note automatically converted into shares of the Company’s Class A Common Stock at a fixed conversion price of $0.30 per share.

As a result of the automatic conversions, the Company issued an aggregate of 4,280,340 shares of Class A Common Stock, consisting of: (i) 1,893,796 shares issued to Atlantic Equity Holdings Inc.; and (ii) 2,386,544 shares issued to Empire Street Capital Inc. No additional consideration was received by the Company in connection with the amendments, assignments, or conversions. Upon issuance of the conversion shares, the applicable amended notes were deemed fully satisfied and extinguished.

Because the promissory notes originally issued to Mr. Wan and New Lite Ventures LLC were assigned to third-party assignees prior to conversion, neither Mr. Wan nor New Lite Ventures LLC received any shares upon the automatic conversion of those notes.

Director Independence

The Board of Directors consists of one member, Mr. Barry Wan, who does not meet the independence requirements of the Nasdaq Stock Market.

Item 14. Principal Accounting Fees and Services

During 2026 and 2025, J&S Associate PLT, the Company’s independent auditors have billed for their services as set forth below. In addition, fees and services related to the audit of the financial statements of the Company for the period ended March 31, 2026 as contained in this Report, are estimated and included for the fiscal year ended March 31, 2025.

	Years ended March 31,
	2026		2025

Audit Fees – J&S Associate PLT	$	56,400		25,000
Audit-Related Fees	$	14,400	$	24,000
All Other Fees	$	-	$	-
Total Fees	$	70,400	$	49,000

Pre-Approval Policy

Our Board as a whole pre-approves all services provided by J&S Associate PLT. For any non-audit or non-audit related services, the Board must conclude that such services are compatible with J&S Associate PLT independence as our auditors.

PART IV

Item 15. Exhibits, Financial Statement Schedules

3.1*		Certificate of Amendment of the Certificate of Incorporation (filed as exhibit to the Form 8-K filed with the SEC on June 21, 2024)

3.2*		By-laws (filed as an Exhibit to Form S-1 filed with the SEC on May 2, 2016)

10.1***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Barry Wan, as assignor, and Empire Street Capital Inc., as assignee, incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.2***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., New Lite Ventures LLC, as assignor, and Atlantic Equity Holdings Inc., as assignee, incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.3***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Hemeihui E-Commerce Co., Ltd., as assignor, Antiaging Doctor Hangzhou Holding Ltd., as original maker, and Atlantic Equity Holdings Inc., as assignee, incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.4***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Hemeihui E-Commerce Co., Ltd., as assignor, Dao Ling Doctor (Zhejiang) Health Management Limited, as original maker, and Empire Street Capital Inc., as assignee, incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.5***		Unanimous Written Consent of the Stockholder, dated November 25, 2025, incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.6***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Barry Wan, in the principal amount of $428,789.50, incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.7***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and New Lite Ventures LLC, in the principal amount of $29,571.00, incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.8***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Hemeihui E-Commerce Co., Ltd., in the principal amount of $538,568.00, relating to Antiaging Doctor Hangzhou Holding Ltd., incorporated by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.9***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Hemeihui E-Commerce Co., Ltd., in the principal amount of $287,174.00, relating to Dao Ling Doctor (Zhejiang) Health Management Limited, incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.10***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Tairan Baohe Insurance Sales Co., Ltd., in the principal amount of $383,598.00, incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

31.1**		Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as Amended.

31.2**		Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as Amended.

32.1**		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**		Inline XBRL Instance Document
101.SCH**		Inline XBRL Taxonomy Extension Schema Document
101.CAL**		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Incorporated by reference to the Company’s Form 8-K as filed with the SEC on June 21, 2024.

** Filed herewith

*** Incorporated by reference to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

SIGNATURES

In accordance with the Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 14th day of July, 2026.

	Antiaging Quantum Living Inc.

	By:	/s/ Barry Wan
		Barry Wan, President
		Chief Executive Officer

In accordance with the requirements of the Securities and Exchange Act of 1934, this report has been signed by the following persons on behalf of the Registrant and in the capacities indicated and on the dates stated.

Dated: July 14, 2026	By:	/s/ Barry Wan
		Barry Wan
		CEO, CFO, Sec. and Director

EXHIBIT INDEX

3.1*		Certificate of Amendment of the Certificate of Incorporation (filed as exhibit to the Form 8-K filed with the SEC on June 21, 2024)

3.2*		By-laws (filed as an Exhibit to Form S-1 filed with the SEC on May 2, 2016)

10.1***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Barry Wan, as assignor, and Empire Street Capital Inc., as assignee, incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.2***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., New Lite Ventures LLC, as assignor, and Atlantic Equity Holdings Inc., as assignee, incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.3***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Hemeihui E-Commerce Co., Ltd., as assignor, Antiaging Doctor Hangzhou Holding Ltd., as original maker, and Atlantic Equity Holdings Inc., as assignee, incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.4***		Assignment and Amendment of Promissory Note, dated November 25, 2025, by and among Antiaging Quantum Living Inc., Hemeihui E-Commerce Co., Ltd., as assignor, Dao Ling Doctor (Zhejiang) Health Management Limited, as original maker, and Empire Street Capital Inc., as assignee, incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.5***		Unanimous Written Consent of the Stockholder, dated November 25, 2025, incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.6***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Barry Wan, in the principal amount of $428,789.50, incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.7***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and New Lite Ventures LLC, in the principal amount of $29,571.00, incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.8***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Hemeihui E-Commerce Co., Ltd., in the principal amount of $538,568.00, relating to Antiaging Doctor Hangzhou Holding Ltd., incorporated by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.9***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Hemeihui E-Commerce Co., Ltd., in the principal amount of $287,174.00, relating to Dao Ling Doctor (Zhejiang) Health Management Limited, incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

10.10***		Promissory Note, dated December 31, 2024, by and between Antiaging Quantum Living Inc. and Tairan Baohe Insurance Sales Co., Ltd., in the principal amount of $383,598.00, incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

31.1**		Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as Amended.

31.2**		Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as Amended.

32.1**		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS**		Inline XBRL Instance Document
101.SCH**		Inline XBRL Taxonomy Extension Schema Document
101.CAL**		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Incorporated by reference to the Company’s Form 8-K as filed with the SEC on June 21, 2024.

Filed herewith

*** Incorporated by reference to the Company’s Registration Statement on Form S-1 filed with the SEC on December 12, 2025.

Antiaging Quantum Living Inc. 10-K